{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:49:21Z","timestamp":1771912161304,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: There is no experience with ciprofloxacin for the treatment of carbapenemase-producing Gram-negative bacteria (CP-GNB) infections. Methods: This is a retrospective single-centre study where we describe the clinical evolution of all consecutive adult patients who received ciprofloxacin monotherapy for the treatment of CP-GNB infections. Primary outcomes were clinical failure (defined as death, lack of clinical improvement or a switch to another drug) at day 14 and 30-day all-cause mortality. Results: Nineteen patients were included. Fifteen (79%) were men, the median age was 74 years (IQR 66\u201379) and the median Charlson comorbidity index was five (IQR 3\u20136.5). The most frequent infections were: nine complicated urinary tract infections, three soft tissue infections and three intra-abdominal infections. Twenty CP-GNBs were isolated (one patient had a coinfection): nine VIM-type-producing Enterobacterales, nine OXA-48-type-producing Enterobacterales and two VIM-type-producing Pseudomonas aeruginosa. Six (32%) patients had positive blood cultures, and one presented with septic shock. The median duration of ciprofloxacin treatment was 14 days (IQR 10\u201315). One patient presented with clinical failure at day 14. There was no 30-day mortality. Two patients exhibited microbiological recurrence at day 90. There were no reported adverse effects. Conclusions: Monotherapy with ciprofloxacin may be an alternative treatment for selected, clinically stable patients with ciprofloxacin-susceptible CP-GNB infections.<\/jats:p>","DOI":"10.3390\/antibiotics13121138","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:20:12Z","timestamp":1732681212000},"page":"1138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria"],"prefix":"10.3390","volume":"13","author":[{"given":"Pablo","family":"Rubi\u00f1an","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, 36312 Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Vi\u00f1ado","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-344X","authenticated-orcid":false,"given":"Nuria","family":"Fern\u00e1ndez-Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-0233","authenticated-orcid":false,"given":"Nieves","family":"Larrosa","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-6038","authenticated-orcid":false,"given":"David","family":"Campany","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-5405","authenticated-orcid":false,"given":"Dolors","family":"Rodr\u00edguez-Pardo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-5909","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Nuvials","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Critical Care Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Sepsis Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"del Barrio-Tofi\u00f1o","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5608-3090","authenticated-orcid":false,"given":"Laura","family":"Escol\u00e0-Verg\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau, 08025 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-2702","authenticated-orcid":false,"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"ref_1","unstructured":"The World Health Organization (2024, November 07). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/364996\/9789240062702-eng.pdf?sequence=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-Producing Organisms: A Global Scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients with Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review","volume":"27","author":"Giannella","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., and Poulakou, G. (2019). The \u201cOld\u201d and the \u201cNew\u201d Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front. Public Health, 7.","DOI":"10.3389\/fpubh.2019.00151"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and A Bonomo, R. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gaibani, P., Giani, T., Bovo, F., Lombardo, D., Amadesi, S., Lazzarotto, T., Coppi, M., Rossolini, G.M., and Ambretti, S. (2022). Resistance to Ceftazidime\/Avibactam, Meropenem\/Vaborbactam and Imipenem\/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050628"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"63","author":"Bonomo","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early Oral Switch to Linezolid for Low-risk Patients with Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study","volume":"69","author":"Willekens","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus Intravenous Antibiotics for Bone and Joint Infection","volume":"380","author":"Li","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-Day Mortality with Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized with Enterobacteriaceae Bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Punjabi, C., Tien, V., Meng, L., Deresinski, S., and Holubar, M. (2019). Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs \u00df-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. Open Forum Infect. Dis., 6.","DOI":"10.1093\/ofid\/ofz364"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106541","DOI":"10.1016\/j.ijantimicag.2022.106541","article-title":"Intravenous to oral antibiotics versus intravenous antibiotics: A step-up or a step-down for extended spectrum \u03b2-lactamase (ESBL)-producing urinary tract infections without concomitant bacteraemia?","volume":"59","author":"Gamble","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2019.05.004","article-title":"Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamase (ESBL) or AmpC \u03b2-lactamase: A propensity score study","volume":"54","author":"Meije","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s15010-016-0968-x","article-title":"Trimethoprim\u2013sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: Retrospective single-center case series","volume":"45","author":"Murri","year":"2017","journal-title":"Infection"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"ofy351","DOI":"10.1093\/ofid\/ofy351","article-title":"The Role of Trimethoprim\/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae","volume":"6","author":"Luterbach","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"O1117","DOI":"10.1111\/1469-0691.12714","article-title":"Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance","volume":"20","author":"Cober","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eimc.2016.05.006","article-title":"Prevalencia en Espa\u00f1a de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y\/o carbapenemasas","volume":"35","author":"Machuca","year":"2017","journal-title":"Enfermedades Infecc. Y Microbiol. Clin. Engl. Ed."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-021-02238-7","article-title":"Distribution of fluoroquinolone resistance determinants in Carbapenem-resistant Klebsiella pneumoniae clinical isolates associated with bloodstream infections in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijantimicag.2017.03.012","article-title":"Carbapenem-resistant Enterobacteriaceae in the community: A scoping review","volume":"50","author":"Kelly","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ofw136","DOI":"10.1093\/ofid\/ofw136","article-title":"Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae: Epidemiological, Microbiological, and Clinical Features","volume":"3","author":"Quintana","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Salamanca-Rivera, E., Palacios-Baena, Z.R., Ca\u00f1ada, J.E., Moure, Z., P\u00e9rez-V\u00e1zquez, M., Calvo-Montes, J., Mart\u00ednez-Mart\u00ednez, L., Cant\u00f3n, R., Carrascoso, G.R., and Pitart, C. (2024). Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain. Infection.","DOI":"10.1007\/s15010-024-02267-0"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101871","DOI":"10.1016\/j.eclinm.2023.101871","article-title":"Risk factors for infections caused by carbapenem-resistant Enterobacterales: An international matched case-control-control study (EURECA)","volume":"57","author":"Paniagua","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/jac\/dkad127","article-title":"Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: Results from ATLAS 2017\u20132019","volume":"78","author":"Gales","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/jac\/dkae140","article-title":"Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: Insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018\u20132021","volume":"79","author":"Lee","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ca\u00f1ada-Garc\u00eda, J.E., Moure, Z., Sola-Campoy, P.J., Delgado-Valverde, M., Cano, M.E., Gij\u00f3n, D., Gonz\u00e1lez, M., Gracia-Ahufinger, I., Larrosa, N., and Mulet, X. (2022). CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli from All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307\/OXA-48 and ST512\/KPC-3. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.918362"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0075122","DOI":"10.1128\/aac.00751-22","article-title":"Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria","volume":"66","author":"Sempere","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients with Bloodstream Infections Caused by Metallo-\u03b2-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rubi\u00f1\u00e1n, P., Vi\u00f1ado, B., Fern\u00e1ndez-Hidalgo, N., Larrosa, N., Sempere, A., Campany, D., Rodr\u00edguez-Pardo, D., Gonz\u00e1lez-L\u00f3pez, J.J., Nuvials, X., and Barrio-Tofi\u00f1o, E.d. (2024, January 30). Ciprofloxacin fo the treatment of infections caused by carbapenemase -producing Gram-negative bacteria. Proceedings of the 27th Congress of Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC), Madrid, Spain.","DOI":"10.3390\/antibiotics13121138"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:40:05Z","timestamp":1760114405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antibiotics13121138"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13121138","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}